Phase I/Ib Study With the Combination of RMC-4630 (SHP2 Inhibitor) and LY3214996 (ERK Inhibitor) in Metastatic KRAS Mutant CRC, PDAC and NSCLC
Latest Information Update: 15 Dec 2023
At a glance
- Drugs Temuterkib (Primary) ; Vociprotafib (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms SHERPA
- 24 Oct 2023 Results (n=11) presented at the 48th European Society for Medical Oncology Congress.
- 01 Jun 2022 Status changed from not yet recruiting to recruiting.
- 09 Mar 2022 Planned initiation date changed from 1 Feb 2022 to 1 Apr 2022.